Beyond the Numbers : Exploring More Completely the Cyberbullying Experiences of Adolescents

Color poster with text and bar graphs.The current project seeks to evaluate qualitative responses to questions about the nature of cyberbullying experiences among a national sample of 5,500 middle and high school students. Consistent with thematic analysis, researchers reviewed responses to several open-ended questions about cyberbullying victimization and perpetration, created a rubric, and categorized the respondent's experience based on the rubric. Preliminary results show wide variation in experiences with cyberbullying, with some students significantly impacted and others not so much. Implications for intervention will also be discussed.University of Wisconsin--Eau Claire Office of Research and Sponsored Programs

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

Abstract Background Treatment of metastatic melanoma patients with immune checkpoint inhibitors is an important standard of care. Side effects are due to immune activation, can affect virtually all organ systems, and are occasionally severe. Although hematologic toxicity has been reported, we present a case of hemophagocytic lymphohistiocytosis (HLH) due to immune checkpoint inhibitor therapy. Case presentation A patient with metastatic melanoma was treated with one course of ipilimumab + nivolumab and presented 3 weeks later with severe anemia and hyperferritinemia. A bone marrow biopsy revealed necrotic tumor cells, infiltrating T cells, and hemophagocytosis. The patient was treated with high-dose steroids; 12 months later, the patient remains off all therapy and in complete remission of both HLH and metastatic melanoma. Conclusions The hemophagocytic syndromes are attributable to dysregulated immune activation and share pathophysiologic mechanisms with immune activation from checkpoint inhibitors. Increasing use of regimens that include immune checkpoint inhibition require vigilant monitoring for immune-activating side effects as they can occasionally be life threatening, as in this case of HLH

C30D usability survey data

This data file contains the participant responses to the 21-item C3OD usability survey (Supplementary File 3) given to clinical research coordinators

Data from: A Curated Cancer Clinical Outcomes Data Base (C3OD) for accelerating patient recruitment in cancer clinical trials

Data used to determine patient eligibility for cancer clinical trials often come from disparate sources that are typically maintained by different groups within an institution, use differing technologies, and are stored in different formats. Collecting data and resolving inconsistencies across sources increase the time it takes to screen eligible patients, potentially delaying study completion. To address these challenges, the Biostatistics and Informatics Shared Resource at The University of Kansas Cancer Center developed the Cancer Curated Clinical Outcomes Database (C3OD). C3OD merges data from the electronic medical record (EMR), tumor registry, bio-specimen and data registry, and allows querying through a single unified platform. By centralizing access and maintaining appropriate controls, C3OD allows researchers to more rapidly obtain detailed information about each patient in order to accelerate eligibility screening. This paper describes the design of this informatics platform as well as initial assessments of its reliability and usability